Biophytis Presented Positive Results of Phase 2-3 COVA Study At The American Thoracic Society International Conference

PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / May 25, 2023 / Biophytis SA (NasdaqCM:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the

Related Keywords

United States ,Brazil ,Belgium ,Massachusetts ,France ,Washington ,Veillet ,Rhôalpes ,Cambridge ,Cambridgeshire ,United Kingdom ,Paris ,France General ,American ,America ,Gewinn Nur ,Agathe Boggio ,Antoine Denry ,Girish Nair ,Nicolas Fellmann ,American Thoracic Society International Conference ,American Thoracic Society ,Company Or Biophytis ,Exchange Commission ,Euronext Growth Paris ,Beaumont Hospital ,Royal Oak ,Renin Angiotensin System ,Marketing Authorization ,Emergency Use Authorization ,Latin America ,Duchenne Muscular Dystrophy ,Euronext Growth ,American Depositary Shares ,Nasdaq Capital Market ,Year Financial Report ,Biophytis ,Resented ,Positive ,Results ,Hase ,Nova ,Study ,Thoracic ,Society ,Nternational ,Conference ,